Abstract | INTRODUCTION:
Phosphodiesterase type 5 inhibitors (PDE5Is) are the leading drugs for the treatment of erectile dysfunction (ED), being recommended as a first line treatment by both the European and US urological guidelines. PDE5Is are highly effective as compared to placebo, well tolerated and have a very low, though not negligible, rate of severe treatment-related adverse events. AREAS COVERED: This paper reviews the safety profile of currently available PDE5Is, comparing them in a broad spectrum ED population and outlining a number of real-life aspects of importance in the real-life everyday clinical setting. EXPERT OPINION: Guidelines unanimously agree in considering PDE5Is as first line treatments for ED when well-tolerated and not contraindicated. Despite the fact that no high-grade evidence comparing the efficacy and the safety for PDE5Is is currently available, published data seem to suggest that there are no major differences in their safety proļ¬les. Moreover, although oral PDE5Is were shown to cause more AEs than placebo, they were generally mild and well tolerated.
|
Authors | Eugenio Ventimiglia, Paolo Capogrosso, Francesco Montorsi, Andrea Salonia |
Journal | Expert opinion on drug safety
(Expert Opin Drug Saf)
Vol. 15
Issue 2
Pg. 141-52
( 2016)
ISSN: 1744-764X [Electronic] England |
PMID | 26752541
(Publication Type: Journal Article, Review)
|
Chemical References |
- Phosphodiesterase 5 Inhibitors
|
Topics |
- Administration, Oral
- Animals
- Erectile Dysfunction
(drug therapy, physiopathology)
- Humans
- Male
- Phosphodiesterase 5 Inhibitors
(administration & dosage, adverse effects, therapeutic use)
- Practice Guidelines as Topic
|